{"title":"肝硬化并发的肝肾综合征的预防","authors":"Abuabara-Franco E, Sáenz-López J, Restom-Arrieta J, Bohórquez-Rivero J, Licona-Vera C, Angulo Mn, Vasquez Cb","doi":"10.16966/2380-5498.227","DOIUrl":null,"url":null,"abstract":"Different methods of prevention and reduction of mortality have been studied, such as the placement of a transjugular intrahepatic portosystemic shunt (TIPS) [4]. This technique has been used successfully in individuals with recurrent ascites with excellent results in terms of morbidity and mortality [5]. However, further trials are needed to consolidate its efficacy in the treatment of hepatorenal dysfunction and its benefit-risk assessment [6-8].","PeriodicalId":92052,"journal":{"name":"International journal of nephrology and kidney failure","volume":"1 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Prevention of Hepatorenal Syndrome, as a Complication of Liver Cirrhosis\",\"authors\":\"Abuabara-Franco E, Sáenz-López J, Restom-Arrieta J, Bohórquez-Rivero J, Licona-Vera C, Angulo Mn, Vasquez Cb\",\"doi\":\"10.16966/2380-5498.227\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Different methods of prevention and reduction of mortality have been studied, such as the placement of a transjugular intrahepatic portosystemic shunt (TIPS) [4]. This technique has been used successfully in individuals with recurrent ascites with excellent results in terms of morbidity and mortality [5]. However, further trials are needed to consolidate its efficacy in the treatment of hepatorenal dysfunction and its benefit-risk assessment [6-8].\",\"PeriodicalId\":92052,\"journal\":{\"name\":\"International journal of nephrology and kidney failure\",\"volume\":\"1 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2022-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"International journal of nephrology and kidney failure\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.16966/2380-5498.227\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"International journal of nephrology and kidney failure","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.16966/2380-5498.227","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Prevention of Hepatorenal Syndrome, as a Complication of Liver Cirrhosis
Different methods of prevention and reduction of mortality have been studied, such as the placement of a transjugular intrahepatic portosystemic shunt (TIPS) [4]. This technique has been used successfully in individuals with recurrent ascites with excellent results in terms of morbidity and mortality [5]. However, further trials are needed to consolidate its efficacy in the treatment of hepatorenal dysfunction and its benefit-risk assessment [6-8].
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
